Back to Global NewsPublished: 25 Feb 2026Download AppJoin TelegramLongeveron's Frailty Trial Surge: Why This 7% Jump Could Redefine Aging Stocks#Longeveron#LGVN#Stem Cell Therapy#Age-Related Frailty#Biotech StocksDownload AppJoin CommunityShare Article